CNTX

Context Therapeutics is a pre-revenue, clinical-stage biopharma developing three T-cell-engager (TCE) bispecific antibodies for solid tumors — CTIM-76 (CLDN6xCD3), CT-95 (MSLNxCD3) and CT-202 (Nectin-4xCD3). There is no product revenue and there won't be for years; the entire investment case is the pipeline. Losses are widening — net loss went from -$10.5M (FY2021) to -$36.1M (FY2025), with FY2025 net income down 35.2% YoY and operating income -$39.7M — and ROE is -59.7% against an accumulated deficit of $130.9M. This is a cash-burning research shell, and the only question is whether the science converts before the money runs out.

What keeps this from an outright avoid is the balance sheet. The company holds $66.0M cash against just $8.02M total liabilities (liabilities/equity 0.13x, no meaningful debt) and $60.5M of equity. At $0.65 on ~91.9M shares the market cap is roughly $59.7M — i.e. the stock trades at or slightly below net cash, so buyers are effectively getting three clinical programs for free. Reported operating cash burn was -$26.4M in FY2025, implying a runway into roughly 2028 before financing, though the -$36.1M P&L loss suggests true burn is heavier and dilution is likely — the MD&A confirms operations have been funded 'primarily through the sale of common stock, warrants, convertible debt and convertible preferred stock.'